Short Interest in Cardio Diagnostics Holdings, Inc. (NASDAQ:CDIO) Decreases By 21.4%

Cardio Diagnostics Holdings, Inc. (NASDAQ:CDIO) saw a large decrease in short interest in February. As of February 28th, there was short interest totalling 1,980,000 shares, a decrease of 21.4% from the February 13th total of 2,520,000 shares. Based on an average daily trading volume, of 5,940,000 shares, the days-to-cover ratio is currently 0.3 days. Currently, 4.2% of the shares of the stock are sold short.

Cardio Diagnostics Price Performance

Shares of NASDAQ:CDIO traded down $0.02 during midday trading on Tuesday, reaching $0.44. 397,423 shares of the company’s stock were exchanged, compared to its average volume of 2,510,117. The company’s 50 day simple moving average is $0.52 and its two-hundred day simple moving average is $0.47. Cardio Diagnostics has a 12 month low of $0.19 and a 12 month high of $1.77.

Institutional Inflows and Outflows

Hedge funds and other institutional investors have recently added to or reduced their stakes in the business. Two Sigma Securities LLC acquired a new position in shares of Cardio Diagnostics in the 4th quarter worth approximately $48,000. Jane Street Group LLC acquired a new position in Cardio Diagnostics during the fourth quarter worth $103,000. Millennium Management LLC bought a new position in shares of Cardio Diagnostics during the fourth quarter valued at $236,000. Finally, Geode Capital Management LLC boosted its stake in shares of Cardio Diagnostics by 97.6% in the 4th quarter. Geode Capital Management LLC now owns 364,387 shares of the company’s stock valued at $334,000 after purchasing an additional 179,978 shares in the last quarter. Institutional investors own 8.06% of the company’s stock.

About Cardio Diagnostics

Cardio Diagnostics Holdings, Inc develops and commercializes epigenetics-based clinical tests for cardiovascular disease. It offers Epi+Gen CHD, a three-year symptomatic coronary heart disease (CHD) risk assessment test targeting CHD events, including heart attacks; and PrecisionCHD, an integrated epigenetic-genetic blood test for the early detection of coronary heart disease.